Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

BioFactura Closes Oversubscribed $1.8M Series A Funding Led by Chairman of the Board Dr. Jeffrey Hausfeld
  • USA - English


News provided by

BioFactura, Inc.

Apr 26, 2016, 13:00 ET

Share this article

Share toX

Share this article

Share toX


Frederick, MD (PRWEB) April 26, 2016 -- BioFactura, Inc., a biopharmaceutical research and manufacturing company, announced today the closing of a $1.8M Series A round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M target. The funds will be used to advance a portfolio of generic biologics, known as biosimilars, to the advanced preclinical stages.

"BioFactura has the capability to efficiently produce high value generic versions of these drugs thereby improving access, reducing costs and potentially enhancing outcomes." Dr. Jeffrey Hausfeld, Chairman of the Board and Chief Medical Officer

Post this

Chief Executive Officer and President, Darryl Sampey founded BioFactura in 2004 as a research and development firm focused on biodefense medical countermeasures for the government. The company’s research has led to BioFactura’s core competency in the development of stable manufacturing cell lines for production of therapeutic protein-based drugs with a focus on monoclonal antibodies. In parallel with the Series A fundraising and in preparation for advanced drug development, BioFactura opened a new 5,500+ sq. ft. headquarters and R&D/manufacturing facility in the Riverside Research Park located in Frederick, MD. This expansion adds significant capabilities to BioFactura in cell line and bioprocess development as well as cGMP Phase I manufacturing at the 250-liter bioreactor scale with all single-use processes. With BioFactura’s continuing commercialization of its patented StableFast™ Biomanufacturing Platform, the Company is well positioned well to bring both biosimilar and novel antibody drugs to market with shorter timelines, lower costs and superior quality manufacturing methods. To date, BioFactura has raised over $10M in funding including two Congressional Special Projects, and has successfully transitioned a novel monoclonal antibody therapeutic against smallpox from research to the Pre-Investigational New Drug application stage.

With BioFactura’s unique patented platform, the Company is rapidly expanding into the growing US Market for biosimilars. “With the Food and Drug Administration recently approving the first biosimilars drugs for use in the US, biosimilars are rapidly becoming the next wave for pharmaceutical manufacturers. Biosimilars are generic biologics which have the potential for broader patient access and significant savings to the US healthcare system,” said CEO and President, Darryl Sampey.

BioFactura’s Chairman of the Board and Chief Medical Officer, Dr. Jeffrey Hausfeld, said, “There are only a few instances where you see the intersection of a high priority unmet need, coupled with an innovative technology and capable team that can deliver a defined solution. Biologics are highly effective medications that have helped scores of patients and potentially achieve cost savings over branded biologics. BioFactura has the capability to efficiently produce high value generic versions of these drugs thereby improving access, reducing costs and potentially enhancing outcomes. This, combined with the company’s continuing novel drug development programs, make it an investment that I am honored to champion, both for our investors as well as the patients we care for.”

About BioFactura Leadership
President and Chief Executive Officer, Darryl Sampey has experience in intellectual property maintenance, contract research and development, platform technology programs, and biopharmaceutical product development. Prior to starting BioFactura, he led both process development and manufacturing teams at Human Genome Sciences, Inc. (HGS) developing new biologics processes and control strategies. Mr. Sampey played key roles in the start-up, commissioning, and validation of HGS’ first cGMP manufacturing facility and associated development laboratories. In 2015, Mr. Sampey expanded BioFactura’s leadership team with the addition of Dr. Jeffrey Hausfeld.

As Chairman of the Board and Chief Medical Officer, Dr. Jeffrey Hausfeld brings a wealth of knowledge to BioFactura as a retired surgeon, entrepreneur and investor. Dr. Hausfeld’s ventures include developing assisted living facilities specializing in Alzheimer's and memory care; consulting for multiple healthcare/life science startups in diagnostics, devices, biotech and Health IT; and serving as the Managing Director of FMS Financial Solutions, a national debt collection and debt acquisition firm specializing in medical and multi-family housing debt collection. Dr. Hausfeld is the Chairman and Founder of the Society of Physician Entrepreneurs (http://www.sopenet.org), a global network focused on educating healthcare and life science professionals in Bioentrepreneurship and Innovation.

Darryl Sampey, BioFactura, Inc., http://www.biofactura.com, +1 301-600-1058, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.